Antibodies to Watch 2019: 10 Years and Counting
The annual “Antibodies to Watch” article series is celebrating its 10th anniversary. Published in the journal mAbs and widely anticipated at the beginning of the new year, these articles have provided updates on the development of clinical antibody therapeutics each year since 2010 and have given readers detailed insight into what is anticipated for the year to come. For this year’s article, Hélène Kaplon and Janice M. Reichert have chosen to commemorate the 10th anniversary and to honor the 2018 Nobel Prizes in Chemistry and in Physiology or Medicine, both of which were given for work that is highly relevant to antibody therapeutics research, by providing a comprehensive overview of all commercial clinical development and approval success rates of antibody therapeutics.
Briefly, they highlight the record number of antibody therapeutics approved in the United States (US) or European Union (EU) in 2018 (12 total: erenumab, fremanezumab, galcanezumab, burosumab, landadelumab, caplacizumab, mogamulizumab, moxetumomab, pasudodox, celiplimab, ibalizumab, tildrakizumab, emapalumab) and antibody therapeutics undergoing regulatory review in the US, EU (4 total) or China (3 total, targeting PD-1). They also included antibodies to watch in 2019 for non-cancer indications (29 total) and cancer indications (33 total). The authors have included detailed tables with information about the various antibodies which we encourage readers to peruse. To read the article, please refer to Hélène Kaplon & Janice M. Reichert (2018): Antibodies to watch in 2019, mAbs, DOI: 10.1080/19420862.2018.1556465.
Chamow & Associates assists companies to develop biologics for clinical testing and welcomes your inquiry.